iTBS for Acute Ischemic Stroke After Thrombectomy
ConditionIschemic Stroke
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorYi Yang
About this trial
The goal of this randomized, single-blind, parallel-controlled clinical trial is to evaluate the efficacy and safety of intermittent theta burst stimulation (iTBS) as an adjunctive therapy for acute anterior circulation ischemic stroke patients who have undergone successful mechanical thrombectomy (MT). The study population includes adults aged 18-85 with NIHSS scores 5-25 post-MT and eTICI≥2b reperfusion.
Eligibility criteria
Qualifiers
1) Age 18-85 years, regardless of gender.
2) Acute ischemic stroke caused by occlusion of the anterior circulation large vessels (internal carotid artery, M1 or M2 segment of the middle cerebral artery), verified by CTA or DSA.
3) Mechanical thrombectomy (MT) performed within 24 hours of symptom onset.
4) Successful Reperfusion: Post-MT eTICI score ≥ 2b.
Disqualifiers
1) Pre-stroke modified Rankin Scale (mRS) score ≥2.
2) PH2-type intracranial hemorrhage on brain CT post-MT.
3) Patients who underwent intracranial stent placement during MT.
4) Contraindications to iTBS: History of epilepsy or seizures, implanted cardiac pacemakers, cochlear implants, or other electronic/magnetic-sensitive devices.
Trial design
Treatments tested in this trial
- intermittent theta burst stimulation
- sham intermittent theta burst stimulation
Treatment groups
178 Participants
are divided into 2 treatment groupsSponsors and collaborators
Yi Yang
Lead sponsor
The First Hospital of Jilin University
Sponsor institution
Source ClinicalTrials.gov